MA47119A - Livraison de protéines au moyen de bactéries à virulence atténuée - Google Patents

Livraison de protéines au moyen de bactéries à virulence atténuée

Info

Publication number
MA47119A
MA47119A MA047119A MA47119A MA47119A MA 47119 A MA47119 A MA 47119A MA 047119 A MA047119 A MA 047119A MA 47119 A MA47119 A MA 47119A MA 47119 A MA47119 A MA 47119A
Authority
MA
Morocco
Prior art keywords
protein
delivery
bacteria
mixed virulence
mixed
Prior art date
Application number
MA047119A
Other languages
English (en)
Other versions
MA47119B1 (fr
Inventor
Marlise Amstutz
Simon Ittig
Christoph Kasper
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of MA47119A publication Critical patent/MA47119A/fr
Publication of MA47119B1 publication Critical patent/MA47119B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01011—Aspartate-semialdehyde dehydrogenase (1.2.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Photovoltaic Devices (AREA)
MA47119A 2016-12-20 2017-12-20 Administration de protéine à base de bactéries à virulence atténuée MA47119B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16205439 2016-12-20
PCT/EP2017/083853 WO2018115140A2 (fr) 2016-12-20 2017-12-20 Livraison de protéines au moyen de bactéries à virulence atténuée

Publications (2)

Publication Number Publication Date
MA47119A true MA47119A (fr) 2019-10-30
MA47119B1 MA47119B1 (fr) 2021-09-30

Family

ID=57629346

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47119A MA47119B1 (fr) 2016-12-20 2017-12-20 Administration de protéine à base de bactéries à virulence atténuée

Country Status (29)

Country Link
US (3) US11518789B2 (fr)
EP (2) EP3957645A1 (fr)
JP (1) JP6976351B2 (fr)
KR (1) KR102569949B1 (fr)
CN (2) CN110325545B (fr)
AU (1) AU2017384611B2 (fr)
BR (1) BR112019012338A2 (fr)
CA (1) CA3046852A1 (fr)
CL (1) CL2019001698A1 (fr)
CO (1) CO2019006675A2 (fr)
CY (1) CY1124488T1 (fr)
DK (1) DK3559022T3 (fr)
EA (1) EA201991157A1 (fr)
ES (1) ES2886672T3 (fr)
HR (1) HRP20211516T1 (fr)
HU (1) HUE055832T2 (fr)
IL (1) IL267346B1 (fr)
LT (1) LT3559022T (fr)
MA (1) MA47119B1 (fr)
MX (1) MX2019007264A (fr)
MY (1) MY192537A (fr)
PE (1) PE20191356A1 (fr)
PH (1) PH12019550092A1 (fr)
PL (1) PL3559022T3 (fr)
PT (1) PT3559022T (fr)
RS (1) RS62303B1 (fr)
SI (1) SI3559022T1 (fr)
SM (1) SMT202100537T1 (fr)
WO (1) WO2018115140A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102648293B1 (ko) 2014-05-21 2024-03-15 우니페르시테트 바젤 세균 기반 단백질 전달
IL259050B2 (en) 2015-11-19 2024-03-01 Univ Basel Bacteria-based protein delivery
EP3377094B1 (fr) 2015-11-19 2021-04-28 Universität Basel Bactéries à virulence atténuée pour le traitement de tumeurs malignes solides
EP3402498A1 (fr) 2016-01-11 2018-11-21 Synlogic, Inc. Microorganismes programmés pour produire des immunomodulateurs et des agents thérapeutiques anticancéreux dans des cellules tumorales
EP3957645A1 (fr) 2016-12-20 2022-02-23 Universität Basel Administration de protéine a virulence atténuée
CA3110870A1 (fr) * 2018-09-06 2020-03-12 Dana-Farber Cancer Institute, Inc. Nucleotidyltransferases de type cgas/dncv et leurs utilisations
CN109825464B (zh) * 2019-01-17 2021-06-15 浙江海洋大学 敲除t6ss-1基因簇的杀香鱼假单胞菌鱼用减毒疫苗
US20220362361A1 (en) * 2019-10-18 2022-11-17 University Of Virginia Patent Foundation Compositions and methods for producing enhanced immune responses and rapid antibody production
WO2022067219A1 (fr) * 2020-09-28 2022-03-31 The Regents Of The University Of Michigan Méthodes et compositions pour inflammation intestinale
MX2023004760A (es) * 2020-10-27 2023-07-21 T3 Pharmaceuticals Ag Suministro de proteinas basado en bacterias.
WO2022164937A1 (fr) * 2021-01-26 2022-08-04 Christopher Bradley Traitement du cancer à l'aide d'antigènes de vaccination par virus à médiation par arnm délivrés par des bactéries atténuées
CN112852698B (zh) * 2021-01-30 2022-11-29 军事科学院军事医学研究院军事兽医研究所 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用
WO2022200492A1 (fr) * 2021-03-25 2022-09-29 T3 Pharmaceuticals Ag Combinaisons pharmaceutiques pour le traitement d'un cancer
PH12023552423A1 (en) * 2021-03-25 2024-02-19 T3 Pharmaceuticals Ag Pharmaceutical combinations for treating cancer
CN113480611B (zh) * 2021-06-28 2022-12-02 武汉大学 Rig-i的半胱天冬酶激活募集结构域抗病毒多肽、载体及其在制备抗病毒药物中的应用
CN113699088B (zh) * 2021-08-27 2023-09-15 集美大学 一株溶藻弧菌pstS基因稳定沉默菌株及其应用
CN114181881A (zh) * 2021-12-15 2022-03-15 浙江农林大学 基于氨基酸改造的新型减毒单增李斯特菌构建方法及应用
EP4482968A4 (fr) * 2022-02-22 2026-03-04 Board Of Regents For The Oklahoma Agricultural And Mech Colleges Compositions et procédés pour une transformation de plante médiée par rhizobium améliorée
CN115109858B (zh) * 2022-06-07 2025-02-11 宁波大学 一种美人鱼发光杆菌美人鱼亚种的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853683T2 (de) 1987-10-07 1995-08-31 Univ Washington Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation.
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
WO2000002996A2 (fr) 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Produits et systemes de recombinaison destines a la secretion de proteines grace a des systemes de secretion de type iii
US6291245B1 (en) * 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
AU2001294834A1 (en) 2000-09-26 2002-04-08 Beth Israel Deaconess Medical Center Recombinant bcg vaccines for the prevention and treatment of cancer
WO2002077249A2 (fr) 2001-03-26 2002-10-03 Universite Catholique De Louvain Souches bacteriennes de type iii ameliorees destinees a une utilisation medicale
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
EP1943344A2 (fr) * 2005-10-04 2008-07-16 The Ludwig Institute for Cancer Research Methodes permettant de stimuler une reponse immunitaire au moyen d'un systeme de distribution d'antigenes bacteriens
WO2008019183A2 (fr) 2006-05-18 2008-02-14 The Regents Of The University Of California Production de biopolymères et de protéines au moyen de systèmes de sécrétion de type iii de bactéries à gram négatif
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2268313A2 (fr) 2008-03-17 2011-01-05 Universitätsklinikum Münster Protéine yopm utilisée comme véhicule pour les molécules cargo et comme agent thérapeutique biologique pour l immunomodulation de réactions inflammatoires
AU2015227479B2 (en) * 2008-11-21 2017-05-04 Københavns Universitet (University Of Copenhagen) Priming of an immune response
JP6283040B2 (ja) * 2013-03-07 2018-02-21 ザ ジェネラル ホスピタル コーポレイション 細菌によるポリペプチド送達のための組成物および方法
EP3049526B1 (fr) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Protéines de fusion se liant au récepteur de l'interleukine 4 et utilisations associées
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
KR102648293B1 (ko) * 2014-05-21 2024-03-15 우니페르시테트 바젤 세균 기반 단백질 전달
EP4137150A1 (fr) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Mutants de délétion de la protéine brachyury, vecteurs sans levure codant pour les mutants de délétion de la protéine brachyury, et leur utilisation
EP3377094B1 (fr) 2015-11-19 2021-04-28 Universität Basel Bactéries à virulence atténuée pour le traitement de tumeurs malignes solides
IL259050B2 (en) 2015-11-19 2024-03-01 Univ Basel Bacteria-based protein delivery
EP3957645A1 (fr) * 2016-12-20 2022-02-23 Universität Basel Administration de protéine a virulence atténuée
EP3570856A2 (fr) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Méthodes de traitement du cancer
CN112601535A (zh) 2018-04-17 2021-04-02 约翰霍普金斯大学 用于癌症的重组治疗干预
WO2022200492A1 (fr) 2021-03-25 2022-09-29 T3 Pharmaceuticals Ag Combinaisons pharmaceutiques pour le traitement d'un cancer
PH12023552423A1 (en) 2021-03-25 2024-02-19 T3 Pharmaceuticals Ag Pharmaceutical combinations for treating cancer

Also Published As

Publication number Publication date
EP3559022A2 (fr) 2019-10-30
SI3559022T1 (sl) 2021-11-30
US20230250138A1 (en) 2023-08-10
KR20190097154A (ko) 2019-08-20
US11518789B2 (en) 2022-12-06
EP3559022B1 (fr) 2021-06-30
CA3046852A1 (fr) 2018-06-28
CN110325545A (zh) 2019-10-11
ES2886672T3 (es) 2021-12-20
US20250368691A1 (en) 2025-12-04
US20200123207A1 (en) 2020-04-23
WO2018115140A2 (fr) 2018-06-28
CO2019006675A2 (es) 2019-09-18
EP3957645A1 (fr) 2022-02-23
AU2017384611A1 (en) 2019-07-04
MX2019007264A (es) 2019-11-18
CL2019001698A1 (es) 2020-01-24
HUE055832T2 (hu) 2021-12-28
JP2020501609A (ja) 2020-01-23
BR112019012338A2 (pt) 2019-11-26
CY1124488T1 (el) 2022-07-22
PH12019550092A1 (en) 2020-03-09
NZ754510A (en) 2024-02-23
RS62303B1 (sr) 2021-09-30
MA47119B1 (fr) 2021-09-30
IL267346B1 (en) 2026-03-01
LT3559022T (lt) 2021-08-25
KR102569949B1 (ko) 2023-08-24
PT3559022T (pt) 2021-08-19
IL267346A (en) 2019-08-29
EA201991157A1 (ru) 2020-01-16
DK3559022T3 (da) 2021-09-27
SMT202100537T1 (it) 2021-11-12
WO2018115140A3 (fr) 2018-08-09
CN118006531A (zh) 2024-05-10
MY192537A (en) 2022-08-26
PE20191356A1 (es) 2019-10-01
HRP20211516T1 (hr) 2021-12-24
JP6976351B2 (ja) 2021-12-08
AU2017384611B2 (en) 2022-10-27
CN110325545B (zh) 2024-02-09
PL3559022T3 (pl) 2021-12-20
US12358955B2 (en) 2025-07-15

Similar Documents

Publication Publication Date Title
MA47119A (fr) Livraison de protéines au moyen de bactéries à virulence atténuée
IL263846B (en) Formulation of a peptide vaccine
SG11202003754YA (en) High concentration protein formulations with reduced viscosity
SI3191502T1 (sl) Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine
DK3922279T3 (da) Præparater til lægemiddelafgivelse og anvendelse heraf
HRP20180810T1 (hr) Pripravci koji sadrže bakterijske sojeve
HRP20182170T1 (hr) Pripravci koji sadrže bakterijske sojeve
IL256652A (en) Therapeutic compositions, combinations, and methods of use
IL268704B (en) Formulations of human anti-rankl antibodies, and methods of using the same
HRP20180501T1 (hr) Pripravci koje sadrže bakterijske sojeve
PT3827845T (pt) Formulações subcutâneas de anticorpos anti-cd38 e suas utilizações
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
EP3491026A4 (fr) Anticorps humains, compositions pharmaceutiques et procédés
HUE051184T2 (hu) Baktériumalapú fehérjeszállítás
DK3576788T3 (da) Farmaceutisk sammensætning med lavt ph, der omfatter t-celle-engagerende antistofkontruktioner
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
IL246837B (en) Antibodies, pharmaceutical compositions and uses thereof
EP3389589C0 (fr) Dispositif d'administration médicale
HUE062579T2 (hu) Baktériumokat tartalmazó orális gyógyszerészeti formuláció
DK3672631T3 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EP3606544A4 (fr) Thérapie au moyen de mini-gènes
EP3436049A4 (fr) Protéine 8 de type angiopoïétine (angptl8)
EA202091567A1 (ru) Химерные белки мти
IL283229A (en) High concentration protein formulation